Preclinical impact of bevacizumab on brain and tumor distribution of irinotecan and temozolomide
Glioblastoma (GBM) is the most common primary malignant brain tumour in adults. Prognosis of GBM patients is poor with median overall survival around 15 months. Temozolomide is the chemotherapeutic agent used in the standard of care of newly diagnosed GBM patients relying on radiotherapy with concur...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | , , , , , , , , |
| Format: | article |
| Published: |
2015
|
| Online Access: | http://hdl.handle.net/10725/4503 http://dx.doi.org10.1007/s11060-015-1717-1 http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php http://link.springer.com/article/10.1007/s11060-015-1717-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|